The CPS is calculated on the basis of the number of PD-L1+ cells (including tumor cells, lymphocytes, and macrophages) in relation to the total tumor cells and is one of the factors influencing the therapeutic choice [132]. The gene discussed is CD274; the disease is neoplasm.